[Demonstration of the central effects of D,L-kawain with EEG brain mapping].
In a double-blind, placebo-controlled EEG-brain-mapping study Saletu et al. demonstrated the encephalotropic effects of single doses of 200, 400 and 600 mg D,L-kawain in healthy volunteers. The substance induced a dose-dependent increase in delta, theta and alpha 1 power, as well as a decrease in alpha 2 and beta power. The shift towards low frequences indicated a sedative effect of higher doses of D,L-kawain. Changes were most pronounced in the frontal regions. The pharmacodynamic peak was reached in the 1st hour; a 2nd peak was seen in the 8th hour. D,L-kawain at a dose of 200 mg had an initial activating effect, followed at a later stage by a mild sedative effect. Self-rating scales suggested activation after 200 mg, but mild sedation after 600 mg. Psychometric performance improved after all D,L-kawain doses; there were no adverse reactions.
Frey
R
R
Psychiatrische Klinik, Universität Wien.
D014151:Anti-Anxiety Agents / Q000008:administration & dosage*; D001008:Anxiety Disorders / Q000188:drug therapy* / Q000503:physiopathology; D001143:Arousal / Q000187:drug effects / Q000502:physiology; D001569:Benzodiazepines; D001570:Benzodiazepinones / Q000008:administration & dosage; D001931:Brain Mapping; D002540:Cerebral Cortex / Q000187:drug effects / Q000503:physiopathology; D000078306:Clobazam; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004569:Electroencephalography / Q000187:drug effects*; D006801:Humans; D016584:Panic Disorder / Q000188:drug therapy* / Q000503:physiopathology; D011753:Pyrones / Q000008:administration & dosage*
D014151:Anti-Anxiety Agents; D001570:Benzodiazepinones; D011753:Pyrones; D001569:Benzodiazepines; D000078306:Clobazam; C011889:kavain
Darstellung zentraler Effekte von D,L-Kavain im EEG-Brain-Mapping.